NCCN Updates Guidelines to Include CSF Testing for Inoperable Gliomas

The updated NCCN recommendations apply to patients unable to undergo surgery due to tumor location, health complications, or personal refusal. By incorporating CSF-based testing for these malignancies, the guidelines now mirror the diagnostic standards long established in broader solid-tumor oncology. Beyond gliomas, the framework continues to support liquid biopsy applications for medulloblastoma, CNS lymphoma, and ependymoma.

This marks the second consecutive year of expansion for CSF-based profiling within the NCCN guidelines, signaling an accelerating move toward liquid biopsy as a standard diagnostic tool. For patients with high-grade gliomas, this approach bypasses the limitations of traditional CSF cytology, offering a more precise pathway for targeted therapeutic intervention.

Belay Diagnostics, which provides the Summit 2.0, Ascent, and Vantage testing platforms, aligns its offerings with these updated requirements for multi-gene panel analysis. The company’s flagship panel, Summit 2.0, recently demonstrated 96% clinical sensitivity and 98% clinical specificity in validation studies published in the journal Cancers. These tests are designed to extract comprehensive genomic data from a single CSF specimen, providing a viable diagnostic alternative for cases where tissue sampling is medically impossible.